PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Open accessThe DOI matches its Crossref record; 145 of the 147 references it cites were found in a registry or an index.
Abstract
PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1) play a crucial role in regulating the immune system and preventing autoimmunity. Cancer cells can manipulate this system, allowing them to escape immune detection and promote tumor growth. Therapies targeting the PD-1/PD-L1 pathway have transformed cancer treatment and have demonstrated significant effectiveness against various cancer types. This study delves into the structure and signaling dynamics of PD-1 and its ligands PD-L1/PD-L2, the diverse PD-1/PD-L1 inhibitors and their efficacy, and the resistance observed in some patients. Furthermore, this study explored the challenges associated with the PD-1/PD-L1 inhibitor treatment approach. Recent advancements in the combination of immunotherapy with chemotherapy, radiation, and surgical procedures to enhance patient outcomes have also been highlighted. Overall, this study offers an in-depth overview of the significance of PD-1/PD-L1 in cancer immunotherapy and its future implications in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials of PD-1/PD-L1 inhibitors have shown durable responses in various cancers, but resistance remains a challenge, often due to alterations in signaling pathways or TME composition (Parvez et al., 2023).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Parvez et al., 2023
The cited source says what the claim attributes to it.
In the citing paper
“The PD-1/PD-L1 pathway is another critical signaling axis in cancer immunotherapy, where cancer cells upregulate PD-L1 to engage PD-1 on T cells, inhibiting their cytotoxic function (Parvez et al., 2023).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Parvez et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
PD-1/PD-L1 pathway: current researches in cancer.
Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 2,283
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · cited 1×
“Durvalumab enhances the ability of the immune system to combat tumor cells (108).”
BackgroundBaas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Handbook of Experimental Pharmacology
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-1-269_2 · Cited by 727
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 504
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 417
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401 · cited 1×
“…world ’ s fi rst PD-1 inhibitor, in 2014, 10 PD-1 inhibitors have been developed pembrolizumab (37), cemiplimab (38), toripalimab (39), sintilimab (40), camrelizumab (41), tislelizumab (42), penpulimab (43), prolgolimab (44), dostarlimab (45), and zimberelimab (46), and fi ve PD-L1 inhibitors…”
BackgroundGut microbiome and its role in colorectal cancer
Rebersek, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09054-2 · Cited by 355
PD-L1 degradation pathway and immunotherapy for cancer
Gou, Q., Dong, C., Xu, H., Khan, B., Jin, J., Liu, Q., Shi, J., & Hou, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03140-2 · Cited by 322
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 292
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Sun, J.-Y., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X.-J., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 279
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review
Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., & Mackiewicz, A. (2023) · Cells · doi:10.3390/cells12172159 · Cited by 241
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y.-S. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 233
Trends in clinical development for PD-1/PD-L1 inhibitors
Xin Yu, J., Hodge, J. P., Oliva, C., Neftelinov, S. T., Hubbard-Lucey, V. M., & Tang, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00182-w · Cited by 222
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Upadhaya, S., Neftelinov, S. T., Hodge, J., & Campbell, J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00030-4 · Cited by 210
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z., & Yang, X. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s267433 · Cited by 199
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
Zhao, S. G., Lehrer, J., Chang, S. L., Das, R., Erho, N., Liu, Y., Sjöström, M., Den, R. B., Freedland, S. J., Klein, E. A., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy141 · Cited by 198
Yang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Almutairi, A. R., McBride, A., Slack, M., Erstad, B. L., & Abraham, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00091 · Cited by 175
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Lin, X., Lu, X., Luo, G., & Xiang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111876 · Cited by 160
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 153
Oba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 147
Sternberg, C. N., Loriot, Y., James, N. D., Choy, E., Castellano, D., López‐Ríos, F., Banna, G. L., Giorgi, U. D., Masini, C., Bamias, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.015 · Cited by 140
PD‐1/PD‐L1‐dependent immune response in colorectal cancer
Payandeh, Z., Khalili, S., Somi, M. H., Mard‐Soltani, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Samadi, N., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29494 · Cited by 137
Monoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 130
Barta, S. K., Zain, J. M., Macfarlane, A. W., Smith, S. M., Ruan, J., Fung, H. C. H., Tan, C. R. C., Yang, Y., Alpaugh, R. K., Dulaimi, E., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.022 · Cited by 129
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 127
Chen, Y., Pei, Y., Luo, J., Huang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01088 · Cited by 117
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1897102 · Cited by 114
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Жулай, Г. А., & Олейник, Е. К. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13129 · Cited by 100
Zhao, X., Shen, J., Ivaturi, V. D., Gopalakrishnan, M., Feng, Y., Schmidt, B. J., Statkevich, P., Goodman, V. L., Gobburu, J. V. S., Bello, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.015 · Cited by 97
Liu, S. M., & Wu, Y.-L. L. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1833857 · Cited by 94
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 92
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02126-1 · Cited by 89
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 89
Burova, E., Hermann, A., Dai, J., Ullman, E., Halász, G., Potocky, T. B., Hong, S., Liu, M., Allbritton, O., Woodruff, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1376 · Cited by 89
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Immunotherapy · doi:10.2217/imt-2021-0026 · Cited by 87
Papadopoulos, K. P., Harb, W. A., Peer, C. J., Hua, Q., Xu, S., Lu, H., Lu, N., He, Y., Xu, T., Dong, R.-P., et al. (2021) · The Oncologist · doi:10.1002/onco.13817 · Cited by 87
N‐glycosylation of PD‐1 promotes binding of camrelizumab
Liu, K., Tan, S., Jin, W., Guan, J., Wang, Q., Sun, H., Qi, J., Yan, J., Chai, Y., Wang, Z., et al. (2020) · EMBO reports · doi:10.15252/embr.202051444 · Cited by 84
Sasikumar, P. G., & Ramachandra, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.752065 · Cited by 80
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
Lee, A., Duggan, S. T., & Deeks, E. D. (2020) · Drugs · doi:10.1007/s40265-020-01302-2 · Cited by 78
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
Tjulandin, S. A., Демидов, Л. В., Moiseyenko, V. M., Анатольевна, П. С., Semiglazova, Т. Y., Odintsova, S., Zukov, R. A., Lazarev, S., Makarova, Y., Nechaeva, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.030 · Cited by 69
Biologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Durvalumab in cancer medicine: a comprehensive review
Argote, J. A., & Dasanu, C. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1635115 · Cited by 64
Sasikumar, P. G., Ramachandra, R. K., Adurthi, S., Dhudashiya, A. A., Vadlamani, S., Vemula, K., Vunnum, S., Satyam, L. K., Samiulla, D. S., Subbarao, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0737 · Cited by 61
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Xu, X., Masubuchi, T., Cai, Q., Zhao, Y., & Hui, E. (2021) · eLife · doi:10.7554/elife.74276 · Cited by 59
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Prestipino, A., & Zeiser, R. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4810 · Cited by 52
Regulation of PD-1 in T cells for cancer immunotherapy
Yu, X., Gao, R., Li, Y., & Zeng, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173240 · Cited by 52
Sun, Y., Li, M., Ma, J., Li, B., Zhu, Y., & Chen, F. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.1098755 · Cited by 52
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Li, M., Zhao, R., Chen, J., Tian, W., Xia, C., Liu, X., Li, Y., Yan, Y., Li, S., Sun, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85329-9 · Cited by 48
Phakham, T., Bulaon, C. J. I., Khorattanakulchai, N., Shanmugaraj, B., Buranapraditkun, S., Boonkrai, C., Sooksai, S., Hirankarn, N., Abe, Y., Strasser, R., et al. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.736299 · Cited by 48
Kim, Y., Vagia, E., de Viveiros, P. A. H., Kang, C. Y., Lee, J. Y., Gim, G., Cho, S., Choi, H., Kim, L., Park, I., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02703-8 · Cited by 48
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 47
Tie, Y., Yang, H. J., Zhao, R., Zheng, H., Yang, D., Zhao, J., & Liu, M. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s188893 · Cited by 45
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 45
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
Kaur, J., Elms, J., Munn, A. L., Good, D. M., & Wei, M. Q. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103417 · Cited by 44
Zucali, P. A., Lin, C., Carthon, B. C., Bauer, T. M., Tucci, M., Italiano, A., Iacovelli, R., Su, W., Massard, C., Saleh, M. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003697 · Cited by 44
Notch Signaling and the Breast Cancer Microenvironment
Shen, Q., & Reedijk, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_12 · Cited by 44
Zhou, Y., Wang, Y., Xia, R.-L., Liu, J., & Ma, X. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.04.19 · Cited by 44
Muth, S. T., Saung, M. T., Blair, A. B., Henderson, M., Thomas, D. L., & Zheng, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.041 · Cited by 43
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Singh, V., Khurana, A., Allawadhi, P., Banothu, A. K., Bharani, K. K., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790963 · Cited by 43
Shi, W., Lv, L., Liu, N., Wang, H., Wang, Y., Zhu, W., Liu, Z., Zhu, J., & Lu, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.016 · Cited by 43
PD-1/PD-L1 pathway: A double-edged sword in periodontitis
Liu, X., Yang, L., & Tan, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114215 · Cited by 43
Bhatia, S., Nghiem, P., Veeranki, S. P., Vanegas, A., Lachance, K., Tachiki, L. M. L., Chiu, K., Boller, E., & Bharmal, M. F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004904 · Cited by 42
Tiragolumab Impresses in Multiple Trials
(2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2020-063 · Cited by 41
Ding, D., Hu, H., Liao, M., Shi, Y., She, L., Yao, L., Zhu, Y., Zeng, S., & Huang, J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01292-3 · Cited by 40
Shalata, W., Weissmann, S., Gabay, S. I., Sheva, K., Saleh, O. A., Jama, A. A., Yakobson, A., & Rouvinov, K. (2022) · Cancers · doi:10.3390/cancers14215451 · Cited by 39
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again
Davis, C. M., & Lewis, K. D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211066147 · Cited by 39
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology
Li, T. R., Chatterjee, M. S., Lala, M., Abraham, A. K., Freshwater, T., Jain, L., Sinha, V. P., de Alwis, D. P., & Mayawala, K. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2170 · Cited by 39
Bagegni, N. A., Davis, A. A., Clifton, K., & Ademuyiwa, F. O. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s293597 · Cited by 39
González-Martı́n, A., Sánchez‐Lorenzo, L., Colombo, N., Christensen, R. D., Heitz, F., Meirovitz, M., Selle, F., Gorp, T. V., Álvarez, N., Sanchez, J., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001633 · Cited by 37
del Muro, X. G., Valderrama, B. P., Medina, A., Cuellar, M. A., Etxániz, O., Sarrió, R. G., Juan-Fita, M. J., Ferrer, F., Rodríguez, I. M., Lendínez‐Cano, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4505 · Cited by 37
TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
Siewe, N., & Friedman, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252620 · Cited by 34
Islam, M. K., & Stanslas, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107870 · Cited by 34
Roviello, G., D’Angelo, A., Generali, D., Pittacolo, M., Ganzinelli, M., Iezzi, G., de Manzini, N., & Sobhani, N. (2019) · Immunotherapy · doi:10.2217/imt-2019-0011 · Cited by 29
Jiao, Y., Liu, M., Luo, N., Guo, H., & Li, J. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104992 · Cited by 29
Lou, B., Wei, H., Yang, F., Wang, S., Yang, B., Zheng, Y. T., Zhu, J., & Yan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736955 · Cited by 28
Wang, B., Bai, W., Ma, H., & Li, F. (2020) · Medical Science Monitor · doi:10.12659/msm.927577 · Cited by 28
Mager, L., Gardeen, S., Carr, D. R., & Shahwan, K. T. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s381471 · Cited by 28
Shang, J., Huang, L., Huang, J., Ren, X., Liu, Y., & Feng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871372 · Cited by 25
Yu, Y., Jin, X., Zhu, X., Xu, Y., Si, W., & Zhao, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206689 · Cited by 24
Jeong, T.-J., Lee, H. T., Gu, N., Jang, Y.-J., Choi, S.-B., Park, U. B., Lee, S.-H., & Heo, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10123154 · Cited by 24
Honma, Y., Shibata, M., Gohda, T., Matsumiya, H., Kumamoto, K., Miyama, A., Morino, K., Koya, Y., Taira, A., Shinohara, S., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6535-20 · Cited by 23
Phetphoung, T., Malla, A., Rattanapisit, K., Pisuttinusart, N., Damrongyot, N., Joyjamras, K., Chanvorachote, P., Phakham, T., Wongtangprasert, T., Strasser, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274737 · Cited by 22
Loeb, D. M., Lee, J. W., Morgenstern, D. A., Samson, Y., Uyttebroeck, A., Lyu, C. J., Van Damme, A., Nysom, K., Macy, M. E., Zorzi, A. P., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03159-8 · Cited by 21
Julien, K., Leung, H. T., Fuertes, C., Mori, M., Wang, M.-J., Teo, J., Weiss, L., Hamilton, S. J., DiFebo, H., Noh, Y. J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0591 · Cited by 21
Dostarlimab: From preclinical investigation to drug approval and future directions
Cicala, C. M., Musacchio, L., Scambia, G., & Lorusso, D. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178220 · Cited by 21
Use of Immuno-Oncology in Melanoma
Smylie, M. (2020) · Current Oncology · doi:10.3747/co.27.5135 · Cited by 19
Avrillon, V., Daniel, C., Boisselier, P., Pechoux, C. L., & CHOUAID, C. (2022) · Lung · doi:10.1007/s00408-022-00511-8 · Cited by 19
Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy
Awadasseid, A., Zhou, Y., Zhang, K., Tian, K., Wu, Y., & Zhang, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114057 · Cited by 19
Wernham, A. G. H., Shah, F., & Velangi, S. (2018) · Clinical and Experimental Dermatology · doi:10.1111/ced.13825 · Cited by 17
Varlotto, J. M., Sun, Z., Ramalingam, S. S., Wakelee, H. A., Lovly, C. M., Oettel, K. R., Masters, G. A., & Pennell, N. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps8584 · Cited by 17
Cemiplimab for locally advanced and metastatic basal cell carcinoma
Damsin, T., Lebas, E., Marchal, N., Rorive, A., & Nikkels, A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2043748 · Cited by 16
Nanocarrier-based activation of necroptotic cell death potentiates cancer immunotherapy
Xia, G., Lei, T.-R., Yu, T., & Zhou, P. (2021) · Nanoscale · doi:10.1039/d0nr05832g · Cited by 16
Ríos‐Viñuela, E., Álvarez, P., Lavernia, J., Serra-Guillén, C., Requena, C., Bernia, E., Diago, A., Llombart, B., & Sanmartín, O. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.04.011 · Cited by 16
A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
Fa’ak, F., Vanegas, D., & Osei, K. M. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.915351 · Cited by 15
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy
Hamilton, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1825679 · Cited by 15
Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154338 · Cited by 15
Jaccard, A., & Ho, P. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0568-y · Cited by 14
Bolze, P., You, B., Lotz, J., Massardier, J., Gladieff, L., Joly, F., Hajri, T., Maucort‐Boulch, D., Bin, S., Roux, A. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.015 · Cited by 13
Zhou, Y., Mu, W., Wang, C., Zhuo, Z., Xin, Y., Li, H., & Wang, C. (2023) · BMC Cancer · doi:10.1186/s12885-023-11536-4 · Cited by 13
Emerging drugs for the treatment of chronic myelomonocytic leukemia
Perez, J. R., & Bravo, G. M. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1854224 · Cited by 12
Nguyen, J., Epling, D., Dolphin, N., Paccaly, A. J., Conrado, D. J., Davis, J. D., & Al-Huniti, N. H. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12855 · Cited by 12
Shen, T. H., Zheng, S., Geng, L., Liu, Z., Xu, J., Lin, B., Qian, J., & Zheng, S. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820979703 · Cited by 10
Routh, E. D., Woodcock, M. G., Beckabir, W., Vensko, S. P., II, Serody, J. S., & Vincent, B. G. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005848 · Cited by 10
Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years
Dumann, K., Artz, N., & Ziemer, M. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2206 · Cited by 9
Augmenting CAR T Cells with PD-1 Blockade
(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2018-165 · Cited by 8
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
Luo, Y., Sun, N., & He, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01022-x · Cited by 7
Powles, T. B., Park, S. H., Voog, É., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H. P., Radulovic, S., Demey, W., Ullén, A., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1631 · Cited by 7
Sakamoto, M., & Jimeno, A. (2023) · Drugs of today · doi:10.1358/dot.2023.59.3.3507759 · Cited by 7
Design of a protease‐activated PD‐L1 inhibitor
Goudy, O. J., Peng, A., Tripathy, A., & Kuhlman, B. A. (2023) · Protein Science · doi:10.1002/pro.4578 · Cited by 6
Wood, L. S., Conway, D., Lapuente, M., Salvador, G., Gomez, S. F., Bullock, A. C., Devgan, G., & Burns, K. D. (2022) · Journal of Infusion Nursing · doi:10.1097/nan.0000000000000465 · Cited by 6
Zhou, Q., Zhao, J., Wang, J., Bao, G., & Gong, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1244 · Cited by 6
Ríos‐Viñuela, E., Álvarez, P., Lavernia, J., Serra-Guillén, C., Requena, C., Bernia, E., Diago, A., Llombart, B., & Sanmartín, O. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.05.001 · Cited by 6
Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: Cold agglutinin disease
Açıkgöz, Ö., Bayramgil, A., Dorukhan, C. G., & Sadri, S. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211033009 · Cited by 5
Akhtar, K., Sravanthi, M. V., D’Angelo, J. C., & Sivapiragasam, A. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221121408 · Cited by 5
Mislang, A. R., Coward, J. I. G., Cooper, A. J., Underhill, C. R., Zheng, Y., Xu, N., Xiao, C., Jin, X., Li, B., Wang, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.178 · Cited by 3
Acute Appendicitis: A Rare Complication from Nivolumab
Patel, C., Purkey, S. C., & Stancher, J. (2021) · The American Journal of Gastroenterology · doi:10.14309/01.ajg.0000785364.58385.99 · Cited by 3
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Cheng, Y., Sun, F., Cao, H., Gai, D., Peng, B., Xu, H., van Rhee, F., Janz, S., Tricot, G. J. K., Shaughnessy, J. D., et al. (2021) · Blood · doi:10.1182/blood-2021-148659 · Cited by 3
Drug discovery of PD-L1 inhibitor Atezolizumab
Guo, X., & Sheng, X. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1253 · Cited by 2
Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies
Nomura, N., Nomura, Y., Sato, Y., & Iwata, S. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.10.008 · Cited by 1
Liu, W., Chen, T., Lai, S., Zhang, G., Liu, G., & Jin, H. (2021) · International Conference on Machine Learning and Computing (ICMLC) · doi:10.1145/3457682.3457767 · Cited by 1
Avelumab use in Merkel cell carcinoma treatment
Dudzisz‐Śledź, M., Zwierzchowska, M., Bylina, E., Rutkowski, P. L., & Czarnecka, A. M. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0048 · Cited by 1
Research works printed but not linked: 2
- 2023, Worldwide cancer incidence statistics, Cancer Res UK
- Preparation, storage and administration of KEYTRUDA® (pembrolizumab), IHCP
Cited by
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
The complexity of immune evasion mechanisms throughout the metastatic cascade
Haynes, N. M., Chadwick, T. B., & Parker, B. S. (2024) · Nature Immunology · doi:10.1038/s41590-024-01960-4 · Cited by 94
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 89
Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 77
Metadata
- Authors
- Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A.
- Affiliations
- Jamia Hamdard (IN)
- Qassim University (SA)
- Tampere University (FI)
- Corresponding author
- Qureshi, Kamal A.
- Farooqi, Humaira
- Aspatwar, Ashok
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-12-01
- Volume
- 14
- Pages
- 1296341-1296341
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10722272
- OpenAlex
- W4389233067
- Cited by
- 216
- References
- 147
- Citations by year
- 2026: 61 · 2025: 108 · 2024: 47
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
- Funders
- Tampereen Yliopisto
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, cancer immunotherapy, immune evasion, PD-1/PD-L1 inhibitors, treatment resistance, combination therapy, tumor immune microenvironment
- MeSH terms
- Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.